mitoNEET as a novel drug target for mitochondrial dysfunction.

Title

mitoNEET as a novel drug target for mitochondrial dysfunction.

Creator

Geldenhuys Werner J; Leeper Thomas C; Carroll Richard T

Publisher

Drug Discovery Today

Date

2014
2014-10

Description

Mitochondrial dysfunction plays an important part in the pathology of several diseases, including Alzheimer's disease and Parkinson's disease. Targeting mitochondrial proteins shows promise in treating and attenuating the neurodegeneration seen in these diseases, especially considering their complex and pleiotropic origins. Recently, the mitochondrial protein mitoNEET [also referred to as CDGSH iron sulfur domain 1 (CISD1)] has emerged as the mitochondrial target of thiazolidinedione drugs such as the antidiabetic pioglitazone. In this review, we evaluate the current understanding regarding how mitoNEET regulates cellular bioenergetics as well as the structural requirements for drug compound association with mitoNEET. With a clear understanding of mitoNEET function, it might be possible to develop therapeutic agents useful in several different diseases including neurodegeneration, breast cancer, diabetes and inflammation.

Subject

Animals; Drug Delivery Systems; Energy Metabolism; Humans; Mitochondria/*metabolism; Mitochondrial Proteins/chemistry/*metabolism; Protein Conformation; Thiazolidinediones/pharmacology

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

1601–1606

Issue

10

Volume

19

Citation

Geldenhuys Werner J; Leeper Thomas C; Carroll Richard T, “mitoNEET as a novel drug target for mitochondrial dysfunction.,” NEOMED Bibliography Database, accessed July 26, 2021, https://neomed.omeka.net/items/show/3548.

Social Bookmarking